US20050136028A1 - Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin - Google Patents

Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin Download PDF

Info

Publication number
US20050136028A1
US20050136028A1 US10/741,867 US74186703A US2005136028A1 US 20050136028 A1 US20050136028 A1 US 20050136028A1 US 74186703 A US74186703 A US 74186703A US 2005136028 A1 US2005136028 A1 US 2005136028A1
Authority
US
United States
Prior art keywords
skin
extract
composition
group
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/741,867
Other languages
English (en)
Inventor
Dmitri Ptchelintsev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avon Products Inc
Original Assignee
Avon Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Products Inc filed Critical Avon Products Inc
Priority to US10/741,867 priority Critical patent/US20050136028A1/en
Assigned to AVON PRODUCTS INC. reassignment AVON PRODUCTS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PTCHELINTSEV, DMITRI
Priority to PCT/US2004/041274 priority patent/WO2005065701A1/fr
Priority to CA2758186A priority patent/CA2758186A1/fr
Priority to CA2541936A priority patent/CA2541936C/fr
Priority to EP04817024A priority patent/EP1725214A4/fr
Assigned to AVON PRODUCTS, INC. reassignment AVON PRODUCTS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ILIC, NEBOJSA, PTCHELINTSEV, DMITRI, RASKIN, ILYA
Publication of US20050136028A1 publication Critical patent/US20050136028A1/en
Priority to US11/880,201 priority patent/US7842316B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9064—Amomum, e.g. round cardamom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/24—Thermal properties
    • A61K2800/242—Exothermic; Self-heating; Heating sensation

Definitions

  • the present invention relates to compositions that improve the aesthetic appearance of skin. More particularly, the present invention relates to topical cosmetic compositions having extracts of Amomum melegueta to treat aging skin.
  • the appearance and physical properties of human skin cells especially keratinocytes, fibroblasts and sebocytes, change with age. In particular, the ability of these cells to transport in and utilize glucose decreases.
  • a loss in take up and utilization of glucose manifests in an increased concentration of glucose in the extra cellular matrix and a decrease in cell metabolism.
  • Decreased cell metabolism reduces both cell replication and cell vitality.
  • a reduction in the rate of replication of basal epidermal cells reduces the thickness of the epidermis and, thus, the skin.
  • increased extra cellular glucose accumulation in the skin leads to what is known as the formation of Advanced Glycation End (AGE) products and the loss of functional properties of collagen and elastin.
  • AGE Advanced Glycation End
  • cyclooxygenase-2 (COX-2) enzyme and tumor necrosis factor (TNF)-alpha enzyme are believed to be responsible for both acute skin inflammation and subacute chronic inflammation, the cumulative degenerative effects of which lead to intrinsic and extrinsic aging.
  • COX-2 cyclooxygenase-2
  • TNF tumor necrosis factor
  • topical compositions that have an effective amount of an extract of Amomum melegueta and optionally a cosmetically acceptable vehicle.
  • a topical composition can be formulated to improve the aesthetic appearance of skin (including lips), particularly to prevent and/or ameliorate the effects of extrinsic and/or intrinsic aging of the skin.
  • Intrinsic aging may include chronological aging.
  • Extrinsic aging may include photoaging from ultraviolet light exposure and the effects of environmental pollution.
  • the effects of skin aging include, but are not limited to: fragile skin, sagging skin, fine lines and/or wrinkles, thinning skin, lack-luster skin, fatigued skin, and dry skin.
  • the present invention also provides a warming effect on skin.
  • the topical composition has an effective amount of an extract of Amomum melegueta .
  • the Amomum melegueta extract can be applied to the skin and/or scalp for a period of time and in an amount sufficient to prevent and/or ameliorate the skin condition.
  • the extract can be applied as a composition of a pure extract or in a cosmetically acceptable vehicle.
  • Amomum melegueta extract is obtained from the Amomum melegueta plant.
  • Amomum melegueta plant is also known by the name of Grains of Paradise. Any part of the plant, such as the roots, can be used to obtain the extract. Over-the-ground parts, such as the leaf, stem, seeds, bark, fruit and flower are preferred. Seeds are most preferred.
  • the extract may be obtained by any known extraction process with any known extraction solvent.
  • the process can include one or more extractions with one or more solvents or mixtures of solvents.
  • Useful extraction solvents include hydrophilic and hydrophobic solvents and any mixtures thereof. Supercritical fluids are also useful extraction solvents. If desired, solvents can be evaporated after extraction, and resulting residues can be used as is or be freeze-dried or reconstituted in another solvent(s) or mixture thereof in which the extract is either soluble, dispersible or suspendable.
  • hydrophilic solvents include water, methanol, ethanol, brine solution, and solutions of solvent with inorganic and organic salts.
  • hydrophobic solvents examples include liquid hydrocarbons, such as butane, pentane, hexane, heptane, and octane, as well as other water-immiscible organic compounds, such as ether, ester, amide, ketone, and aldehyde.
  • Most preferred water-immiscible/hydrophobic solvents include hexane, diethyl ether, octanol, hexanol, and heptanol.
  • the extract can also be extracted with organic solvents that are partially water miscible and/or completely water miscible.
  • organic solvents include ethyl acetate; methyl acetate; lower ketones having no more than 4 carbon atoms, such as acetone; lower aldehydes having no more than 3 carbons, such as formaldehyde and acetaldehyde; and lower acid anhydrides, such as acetic acid anhydrides.
  • An example of a useful supercritical solvent is liquid carbon dioxide.
  • the effective amount of Amomum melegueta extract and the duration of its application will vary with the particular condition being treated, the age and physical condition of the person, the severity of the condition, the nature of concurrent therapy, the particular topical vehicle utilized, and like factors in the knowledge and expertise of those skilled in the art.
  • the duration of application may be once or twice a day for a period of at least one week, two weeks or more.
  • compositions of the present invention may take the form of a pure extract or an extract in combination with a cosmetically acceptable vehicle and/or additional ingredients.
  • Amomum melegueta extract is present from about 0.0001 weight percent (wt %) to about 90 wt % based on the total weight of the composition. More preferably, the extract is present from about 0.001 wt % to about 50 wt %. Most preferably, the extract is present from about 0.01 wt % to about 15 wt %.
  • active amount of Amomum melegueta extract absent diluent, solvent, or any other ingredient added for bulk.
  • all weight percentages disclosed herein are based on the total weight of the composition unless otherwise noted.
  • the present invention preferably includes a cosmetic vehicle.
  • Such vehicles may take the form of any known in the art suitable for application to skin or scalp. These vehicles may include water; vegetable oils; mineral oils; esters such as octal palmitate, isopropyl myristate and isopropyl palmitate; ethers such as dicapryl ether and dimethyl isosorbide; alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl alcohol, cetearyl alcohol, stearyl alcohol and biphenyl alcohol; isoparaffins such as isooctane, isododecane and is hexadecane; silicone oils such as cyclomethicone, dimethicone, dimethicone cross-polymer, polysiloxanes and their derivatives, preferably organomodified derivatives; hydrocarbon oils such as mineral oil, petrolatum, isoeicosane and polyisobutene; polyols such as propylene glycol,
  • compositions have about 0.01 wt % to about 60 wt % of the vehicle based on the total weight of the composition. More preferred compositions have about 1 wt % to about 30 wt % of the vehicle. Most preferred compositions have about 2 wt % to about 20 wt % of the vehicle.
  • the present composition can be made into any suitable product form, such as aerosol, cake, cream, ointment, emulsion, essence, foam, gel, lotion, mousse, paste, patch, pencil, serum, solution, towelette, mask, body wrap, spray and stick. If desired, the composition can also be formulated into make-up cosmetics, shampoos and conditioners.
  • the composition may also have one or more of the following optional additional ingredients: anesthetics; anti-allergenic; antimicrobials; antifungals; anti-inflammatories; antiseptics; chelating agents; colorants; depigmenting agents; emollients, such as dimethicone, polysilicones and cyclomethicone; exfollients, such as retinal, retinol and retinoic acid; fragrances; emulsifiers; humectants; insect repellents; lubricants; moisturizers; pharmaceutical agents; preservatives; skin penetration enhancers; skin protectants; stabilizers; sunscreens; surfactants; thickeners; viscosity modifiers; and vitamins.
  • anesthetics such as anti-allergenic; antimicrobials; antifungals; anti-inflammatories; antiseptics; chelating agents; colorants; depigmenting agents; emollients, such as dimethicone, polysilicone
  • Particularly useful additional ingredients are vitamins.
  • the extract can be combined with vitamins such as vitamin A, vitamins of the B group, vitamin C, vitamin E, and derivatives thereof.
  • Useful derivatives include retinal, retinol, retinoic acid, and other related compounds having retinoid or retinoid-like activity, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, tocopheryl ascorbyl phosphate, and ascorbyl tocopheryl maleate.
  • Preferred compositions have about 0.001 wt % to about 50 wt % vitamins based on the total weight of the composition. More preferred compositions have about 0.025 wt % to about 25 wt % vitamins. Most preferred compositions have about 0.025 wt % to about 25 wt % vitamins.
  • sunscreens are those with a broad range of UVB and UVA protection, such as octocrylene, avobenzone (Parsol 1789), octyl methoxycinnamate, homosylate, benzophenone, camphor derivatives, zinc oxide, and titanium dioxide.
  • Preferred compositions have about 0.01 wt % to about 70 wt % sunscreens based on the total weight of the composition. More preferred compositions have about 0.1 wt % to about 60 wt % sunscreens. Most preferred compositions have about 1 wt % to about 45 wt % sunscreens.
  • exfoliating agents such as alphahydroxyacids, betahydroxyacids, oxa acids, oxa diacids, and their derivatives such as esters, anhydrides and salts thereof.
  • a most preferred exfoliating agent is glycolic acid.
  • Preferred compositions have about 0.1 wt % to about 80 wt % exfoliating agents based on the total weight of the composition. More preferred compositions have about 1 wt % to about 40 wt % exfoliating agents. Most preferred compositions have about 1 wt % to about 15 wt % exfoliating agents.
  • the anti-inflammatories may be of synthetic, natural or semi-synthetic origin.
  • the anti-inflammatories may be steroidal or non-steroidal.
  • Useful examples include, but are not limited to, mangostin, eysenhardtia polistachya (Palo Azul) wood extract, rosemary extract, camphor, salicylates, hydrocortisone, aspirin, indomethacin, mefenamic acid and derivatives thereof.
  • Preferred compositions have about 0.01 wt % to about 25 wt % anti-inflammatories based on the total weight of the composition. More preferred compositions have about 0.1 wt % to about 15 wt % anti-inflammatories. Most preferred compositions have about 0.5 wt % to about 10 wt % anti-inflammatories.
  • compositions of the present invention may be topically applied to the skin and/or scalp to reduce the extrinsic and/or intrinsic aging on and to enhance to the aesthetic appearance of the skin and/or scalp, as well as to provide a warming effect on the skin and/or scalp.
  • the effects of skin aging include, for example, fragile skin, sagging skin, fine lines and/or wrinkles, thinning skin, lack-luster skin, fatigued skin, dry skin, skin irritation, skin sensitivity, dark eye circles, puffy skin around eyes, irregular skin pigmentation, and melasma.
  • Topically applying compositions of the present invention to the skin can enhance and improve the aesthetic appearance of skin by, among other improvements, reducing skin irritation, decreasing skin fragility; preventing and reversing deterioration of collagen and/or elastin; preventing skin atrophy; promoting/accelerating cell turnover; improving skin firmness/plumpness; improving skin texture; decreasing fine lines and wrinkles; improving skin tone; enhancing skin thickness; restoring skin luster; minimizing signs of fatigue; reducing skin dryness; reducing skin itchiness; reducing skin redness; reducing sensitivity to chemical, mechanical or radiation impact; reducing propensity of the skin to flush and blush; reducing dark circles and puffiness in the periorbital eye area; reducing frown lines on the forehead and laugh lines around the mouth; increasing cell proliferation; decreasing the extent and/or duration of bruising visible after physical trauma; reducing blotchiness and irregular skin pigmentation; treating or ameliorating melasma; treating or ameliorating skin hyperpigmentation; treating or ameliorating foliculitis barbae and
  • the calorimetric COX (ovine) inhibitor screening assay was used to test the COX-2 inhibitory activity of the Amomum melegueta extract.
  • This assay uses the peroxidase component cyclooxygenase to measure the peroxidase activity colorimetrically by monitoring appearance of oxidized calorimetric substrate.
  • the enzyme was added in the wells of a plate followed by the ethanolic solution of calorimetric substrate.
  • the reagents were carefully mixed by shaking the plate.
  • the colorimetric substrate solution was added to the wells followed by addition of COX-2 substrate, arachidonic acid. The plate was again carefully shaken. Inhibitory activity was calculated from these absorbance readings.
  • Commercial drug and COX-2 inhibitor, Vioxx (Merck, Inc.) was used as a positive control.
  • the Amomum melegueta extract demonstrated high inhibitory activity against the enzyme similar to the commercial drug Vioxx (Merck, Inc.) used as a control.
  • the level of inhibition for the Amomum melegueta extract was 92% compared to 90% for Vioxx.
  • ELISA enzyme linked immunoassay
  • This assay employed the quantitative sandwich enzyme immunoassay technique in which a monoclonal antibody specific for TNF-alpha has been pre-coated onto a microtiter plate.
  • Culture supernatants from cells exposed to the active material were pipetted into separate wells. TNF-alpha in the supernatant was bound to the plate via the immobilized antibody. After several washes to remove unbound antibody, an enzyme-linked polyclonal antibody specific for TNF-alpha was added to each well. Following a wash to remove unbound antibody-enzyme reagent, a substrate solution was added to the wells. Color develops in proportion to the amount of TNF-alpha bound in the initial step. The results of the tests showed that the Amomum melegueta extract provided a 60 to 90% degree of TNF-alpha inhibition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
US10/741,867 2003-12-19 2003-12-19 Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin Abandoned US20050136028A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/741,867 US20050136028A1 (en) 2003-12-19 2003-12-19 Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin
PCT/US2004/041274 WO2005065701A1 (fr) 2003-12-19 2004-12-09 Compositions cosmetiques comportant des extraits d amomum melegueta et procedes de traitement de la peau
CA2758186A CA2758186A1 (fr) 2003-12-19 2004-12-09 Compositions cosmetiques comportant des extraits d'amomum melegueta et procedes de traitement de la peau
CA2541936A CA2541936C (fr) 2003-12-19 2004-12-09 Compositions cosmetiques comportant des extraits d'amomum melegueta et procedes de traitement de la peau
EP04817024A EP1725214A4 (fr) 2003-12-19 2004-12-09 Compositions cosmetiques comportant des extraits d'amomum melegueta et procedes de traitement de la peau
US11/880,201 US7842316B2 (en) 2003-12-19 2007-07-20 Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/741,867 US20050136028A1 (en) 2003-12-19 2003-12-19 Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/880,201 Continuation US7842316B2 (en) 2003-12-19 2007-07-20 Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin

Publications (1)

Publication Number Publication Date
US20050136028A1 true US20050136028A1 (en) 2005-06-23

Family

ID=34678290

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/741,867 Abandoned US20050136028A1 (en) 2003-12-19 2003-12-19 Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin
US11/880,201 Expired - Fee Related US7842316B2 (en) 2003-12-19 2007-07-20 Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/880,201 Expired - Fee Related US7842316B2 (en) 2003-12-19 2007-07-20 Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin

Country Status (4)

Country Link
US (2) US20050136028A1 (fr)
EP (1) EP1725214A4 (fr)
CA (2) CA2541936C (fr)
WO (1) WO2005065701A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112105A1 (en) * 2008-10-30 2010-05-06 Access Business Group International Llc Antimicrobial efficacy of aframomum Melegueta extract against propionibacterium acnes
US9675543B2 (en) 2012-12-11 2017-06-13 Avon Products, Inc. Method of improving aging appearance of skin by modulation of WIPI-1
US9687440B2 (en) 2009-12-29 2017-06-27 Avon Products, Inc CGRP compositions and uses thereof
EP2659004B1 (fr) * 2010-12-30 2017-08-30 Avon Products, Inc. Modulation de la dynéine dans la peau
CN117562838A (zh) * 2023-06-20 2024-02-20 广东梵蜜琳生物科技有限公司 一种含植物提取物的舒缓组合物及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1800651B1 (fr) * 2004-08-30 2016-03-09 Kao Corporation Agent reducteur des rides et composition a usage cutane externe comprenant ledit agent
EP3299026B1 (fr) * 2016-09-22 2020-05-27 Dr. Willmar Schwabe GmbH & Co. KG Extraits de graines d'especes d'aframomum et leurs utilisation
FR3075638B1 (fr) * 2017-12-22 2020-03-13 Lvmh Recherche Compositions cosmetiques notamment a activite anti-vieillissement comprenant un extrait vert de la plante aframomum angustifolium ou longoza

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053222A (en) * 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
US5879682A (en) * 1995-11-24 1999-03-09 Peya Biotech Inc Aframonum seeds for improving penile activity
US6063381A (en) * 1993-05-19 2000-05-16 Staggs; Jeff J. Therapeutic uses of pungent botanicals and their related compounds
US6071541A (en) * 1998-07-31 2000-06-06 Murad; Howard Pharmaceutical compositions and methods for managing skin conditions
US6217852B1 (en) * 1998-08-15 2001-04-17 Skinnovative Dermatologic Concepts, L.L.C. Personal cleansing compositions having photoprotective agents
US6593371B1 (en) * 1993-05-19 2003-07-15 Jeff J. Staggs Treatment for wart and related disorders
US6607736B2 (en) * 1999-12-20 2003-08-19 Shiseido Company, Ltd. Skin preparations for external use
US20040067245A1 (en) * 2000-12-20 2004-04-08 Harish Mahalingam Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US20050058729A1 (en) * 1993-05-19 2005-03-17 Staggs Jeff J. Treatment for bacterial infections and related disorders
US20050095628A1 (en) * 2003-09-12 2005-05-05 Krempin David W. Program for regulating health conditions
US20050260290A1 (en) * 2004-05-20 2005-11-24 Rutgers, The State University Of New Jersey Botanical anti-inflammatory compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3164455B2 (ja) * 1993-02-18 2001-05-08 ポーラ化成工業株式会社 角層修復促進剤
GB9707978D0 (en) * 1997-04-21 1997-06-11 Procter & Gamble Throat soothing compositions
EP1370272A1 (fr) * 2001-03-02 2003-12-17 Biopharmacopae Design International Inc. Inhibiteurs de proteases extracellulaires
EP1323356B1 (fr) * 2001-12-27 2006-03-15 Symrise GmbH & Co. KG Utilisation d'amides féruliques comme agents aromatisants
WO2005074959A1 (fr) * 2004-02-05 2005-08-18 Access Business Group International Llc Composition anti-allergique et methode associee

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053222A (en) * 1989-06-07 1991-10-01 Shiseido Company Ltd. Hair cosmetic composition
US6063381A (en) * 1993-05-19 2000-05-16 Staggs; Jeff J. Therapeutic uses of pungent botanicals and their related compounds
US6593371B1 (en) * 1993-05-19 2003-07-15 Jeff J. Staggs Treatment for wart and related disorders
US20050058729A1 (en) * 1993-05-19 2005-03-17 Staggs Jeff J. Treatment for bacterial infections and related disorders
US5879682A (en) * 1995-11-24 1999-03-09 Peya Biotech Inc Aframonum seeds for improving penile activity
US6071541A (en) * 1998-07-31 2000-06-06 Murad; Howard Pharmaceutical compositions and methods for managing skin conditions
US6217852B1 (en) * 1998-08-15 2001-04-17 Skinnovative Dermatologic Concepts, L.L.C. Personal cleansing compositions having photoprotective agents
US6607736B2 (en) * 1999-12-20 2003-08-19 Shiseido Company, Ltd. Skin preparations for external use
US20040067245A1 (en) * 2000-12-20 2004-04-08 Harish Mahalingam Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin
US20050095628A1 (en) * 2003-09-12 2005-05-05 Krempin David W. Program for regulating health conditions
US20050260290A1 (en) * 2004-05-20 2005-11-24 Rutgers, The State University Of New Jersey Botanical anti-inflammatory compositions and methods

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112105A1 (en) * 2008-10-30 2010-05-06 Access Business Group International Llc Antimicrobial efficacy of aframomum Melegueta extract against propionibacterium acnes
US9687440B2 (en) 2009-12-29 2017-06-27 Avon Products, Inc CGRP compositions and uses thereof
EP2659004B1 (fr) * 2010-12-30 2017-08-30 Avon Products, Inc. Modulation de la dynéine dans la peau
US9675543B2 (en) 2012-12-11 2017-06-13 Avon Products, Inc. Method of improving aging appearance of skin by modulation of WIPI-1
CN117562838A (zh) * 2023-06-20 2024-02-20 广东梵蜜琳生物科技有限公司 一种含植物提取物的舒缓组合物及其应用

Also Published As

Publication number Publication date
WO2005065701A1 (fr) 2005-07-21
US20070264364A1 (en) 2007-11-15
EP1725214A4 (fr) 2009-04-15
US7842316B2 (en) 2010-11-30
CA2541936C (fr) 2013-05-14
CA2541936A1 (fr) 2005-07-21
CA2758186A1 (fr) 2005-07-21
EP1725214A1 (fr) 2006-11-29

Similar Documents

Publication Publication Date Title
CA2245125C (fr) Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
CA2185037C (fr) Extrait d'iridacees et compositions le contenant
US7842316B2 (en) Cosmetic compositions having extracts of Amomum melegueta and methods of treating skin
TW201206494A (en) Use of Tiliacora triandra in cosmetics and compositions thereof
US20100062086A1 (en) Compositions and Methods of Their Use for Improving the Condition and Appearance of Skin
EP1278532B1 (fr) Extrait de vegetal de l'espece olea europaea comme inhibiteur de no-synthase et utilisations
FR3059231A1 (fr) Composition comprenant un extrait de truffe et une dihydrochalcone
US20040126351A1 (en) Topical composition having natural skin anti-irritant ingredient and method of use
CN101048134B (zh) 植物提取物用于预防和/或减轻局部施用化妆品期间的主观不适和/或刺激征兆的应用
EP3801778B1 (fr) Utilisation d'un extrait de bixa orellana
TW201642849A (zh) 包括芝麻素之組成物、其製造方法及用於皮膚抗老化及皮膚美白應用之用途
JP2015508815A (ja) Ｃｐｔ−１調節剤及びその組成物としてのスターフルーツ抽出物の使用
US20050153003A1 (en) Anti-aging cosmetic composition and method of application
EP2519223A1 (fr) Agent pour la stimulation de l'expression de loxl
US20090297628A1 (en) Use of iron in the form of a stone extract as stimulus of the synthesis of collagen by skin fibroblasts
WO2000027351A1 (fr) Utilisation d'un extrait d'au moins un vegetal du genre ocimum
HK1198007A (en) Use of starfruit extract as a cpt-1 modulator and compositions thereof
FR2968988A1 (fr) Huile essentielle de fabiana imbricata a titre d'agent apaisant.
HK1110508B (en) Compositions and methods of their use for improving the condition and appearance of skin
HK1110508A1 (en) Compositions and methods of their use for improving the condition and appearance of skin
HK1158966B (en) Compositions comprising an nfkb-inhibitor and a tropoelastin promoter
HK1158966A1 (en) Compositions comprising an nfkb-inhibitor and a tropoelastin promoter

Legal Events

Date Code Title Description
AS Assignment

Owner name: AVON PRODUCTS INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PTCHELINTSEV, DMITRI;REEL/FRAME:015224/0824

Effective date: 20040108

AS Assignment

Owner name: AVON PRODUCTS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PTCHELINTSEV, DMITRI;RASKIN, ILYA;ILIC, NEBOJSA;REEL/FRAME:016591/0121;SIGNING DATES FROM 20050328 TO 20050415

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION